French AI startup Mistral launched its new Mistral 3 family of open-weight models on Tuesday, a launch that aims to prove it can lead in making AI publicly available and serve business clients better ...

ZURICH, Sept 11 (Reuters) - Swiss lawmakers are seeking to water down government proposals to help prevent financial crime, saying the country needs to stay competitive in global cross-border wealth ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

In forecasting economic time series, statistical models often need to be complemented with a process to impose various constraints in a smooth manner. Systematically imposing constraints and retaining ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Robert Knight Archive/Redferns Open tunings are very popular with slide players as they ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal will allow AML ...

Ivosidenib combined with azacitidine extended median overall survival to 29.3 months compared with 7.9 months for placebo plus azacitidine in newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutated ...

Emulation is inherently slower than native execution, but there are several ways to optimize the performance of your Qiling scripts, especially for demanding tasks like fuzzing or large-scale analysis ...

Belonging to a fintech field, you know how much trust matters. Yes, trust is everything. And if your customers don’t feel safe while making payments, they won’t return. You know this already. But what ...

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies. The FDA cleared the investigational new drug (IND) application for ...

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...